ABSTRACT
Rationale Chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are debilitating diseases associated with divergent histopathological changes in the lungs. At present, due to cost and technical limitations, profiling cell types is not practical in large epidemiology cohorts (n>1000). Here, we used computational deconvolution to identify cell types in COPD and IPF lungs whose abundances and cell type-specific gene expression are associated with disease diagnosis and severity.
Methods We analyzed lung tissue RNA-seq data from 1026 subjects (COPD, n=465; IPF, n=213; control, n=348) from the Lung Tissue Research Consortium. We performed RNA-seq deconvolution, querying thirty-eight discrete cell-type varieties in the lungs. We tested whether deconvoluted cell-type abundance and cell type-specific gene expression were associated with disease severity.
Results The abundance score of twenty cell types significantly differed between IPF and control lungs. In IPF subjects, eleven and nine cell types were significantly associated with forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO), respectively. Aberrant basaloid cells, a rare cells found in fibrotic lungs, were associated with worse FVC and DLCO in IPF subjects, indicating that this aberrant epithelial population increased with disease severity. Alveolar type 1 and vascular endothelial (VE) capillary A were decreased in COPD lungs compared to controls. An increase in macrophages and classical monocytes was associated with lower DLCO in IPF and COPD subjects. In both diseases, lower non-classical monocytes and VE capillary A cells were associated with increased disease severity. Alveolar type 2 cells and alveolar macrophages had the highest number of genes with cell type-specific differential expression by disease severity in COPD and IPF. In IPF, genes implicated in the pathogenesis of IPF, such as matrix metallopeptidase 7, growth differentiation factor 15, and eph receptor B2, were associated with disease severity in a cell type-specific manner.
Conclusion Utilization of RNA-seq deconvolution enabled us to pinpoint cell types present in the lungs that are associated with the severity of COPD and IPF. This knowledge offers valuable insight into the alterations within tissues in more advanced illness, ultimately providing a better understanding of the underlying pathological processes that drive disease progression.
Competing Interest Statement
Dr. Hersh reports grant support from Bayer, Boehringer-Ingelheim, and Vertex, and consulting fees from Chiesi, Sanofi, and Takeda, unrelated to this manuscript. Dr. Silverman reports grant support from Bayer and Northpond Laboratories. Dr. Cho reports grant support from Bayer. Dr. DeMeo reports grant support from Bayer and Alpha-1 Foundation. Dr. Castaldi reports grant support from Bayer, Sanofi and consulting fees from Verona Pharmaceuticals. Dr. Yun reports grant support from Bayer and consulting fees from Bridge Biotherapeutics, and travel reimbursement from the Korean Academy of Tuberculosis and Respiratory Disease unrelated to this manuscript. Dr. Flaherty reports grant funding from Boehringer Ingelheim unrelated to this manuscript. Dr. Martinez reports grant supports from NHLBI, AstraZeneca, Chiesi, Boehringer-Ingelheim, GalaxoSmithCline, Novartis, Polarean, Sanofi/Regeneron, Sunovion, and TEVA Pharmaceuticals. Dr. Martinez reports receiving consulting fee from AstraZeneca, Boehringer-Ingelheim and Bristol Myers Squibb. Dr. Wise reports receiving consulting fees from Boehringer-Ingelheim, AstraZenica, Abb-Vie, and Galderma.
Funding Statement
Present work was supported by grants from NHLBI (R01HL166231, P01HL114501, R01HL133135, and X01HL139404), K25 HL136846, K08 HL146972, Alpha-1 Foundation Research Grant, and TOPMed Fellowship. MHC was supported by R01HL162813, R01HL153248, R01HL14.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The participating centers Institutional Review Boards approved the study, and all subjects provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# co-senior authors.
We originally missed one of the authors, Dr. Lucas Barwick, in the medRxiv author list by mistake. We corrected this and everything else remain the same.
List of Abbreviations
- ATI
- alveolar type 1 pneumocytes
- ATII
- alveolar type 2 pneumocytes
- COPD
- chronic obstructive pulmonary disease
- DLCO
- diffusing capacity for carbon monoxide
- FACS
- fluorescence-activated cell sorting
- FDR
- false discovery rate
- FEV1
- forced expiratory volume in one second
- FVC
- forced vital capacity
- IIPs
- idiopathic interstitial pneumonias
- ILC A
- type A innate lymphoid cells
- ILD
- interstitial lung disease
- IPF
- idiopathic pulmonary fibrosis
- IQR
- interquartile range
- LTRC
- Lung Tissue Research Consortium
- PPI
- protein-protein interaction
- RNA-seq
- RNA sequencing
- SMC
- smooth muscle cells
- SMC
- smooth muscle cells
- TGF-β
- transforming growth factor beta
- VE Capillary A
- vascular endothelial - aerocyte capillary
- VE Capillary B
- vascular endothelial - general capillary
- VE Venous
- vascular endothelial venous cells
- cMonocyte
- classical monocytes
- ncMonocyte
- non-classical monocytes
- pDC
- plasmacytoid dendritic cells, and
- scRNA-seq
- single-cell RNA sequencing
